Eli Lilly Reports Positive TOGETHER-PsO Trial Results for Taltz and Zepbound Combination in Psoriasis and Obesity

on

27.1% of patients receiving Taltz and Zepbound achieved complete skin clearance (PASI 100) and at least 10% weight loss at 36 weeks, compared to 5.8% for Taltz monotherapy1

The TOGETHER-PsO Phase IIIb trial enrolled 274 adults with moderate to severe plaque psoriasis and obesity or overweight status1

For complete skin clearance alone (PASI 100), 40.6% of combination therapy patients achieved this outcome versus 29% with Taltz monotherapy, representing a 40% relative increase1

Taltz is a monoclonal antibody targeting interleukin-17A (IL-17A), while Zepbound is a dual GIP/GLP-1 receptor agonist for obesity management1

Adverse events with combination therapy were mainly mild to moderate, with diarrhea, nausea, injection site reactions, and constipation being most frequently reported1

The trial met its primary endpoint and all key secondary endpoints at 36 weeks3

All participants received dietary advice and guidance on increasing physical activity throughout the 52-week study1

Sources:

1. https://www.clinicaltrialsarena.com/news/lilly-positive-topline-pso-trial/

3. https://www.americanpharmaceuticalreview.com/1315-News/624171-Lilly-Reports-Positive-Phase-3B-Results-for-Taltz-Zepbound-Combo-for-Psoriasis-Obesity/